Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026

ByMike Stenberg

July 17th 2026

Midyear 2026 Check-In: Agentic AI Cuts Deviation Investigations by 50%

ByMegha Sinha,Zachary Zubulake

July 17th 2026

Brent Wilhelm, Senior Vice President of Global Supply Chain, Cencora

Brent Wilhelm on Why Drug Shortages Persist Despite Available Inventory

ByBrent Wilhelm,Zachary Zubulake

July 16th 2026

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

ByBrian Drapeau

July 16th 2026

Topical Corticosteroid Bioequivalence Guidance Ends 30-Year Wait

The Implications of the FDA’s New Finalized Guidance Documents

ByZachary Zubulake

July 16th 2026

April 2003

Articles in this issue

Related Content

From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026

Midyear 2026 Check-In: Agentic AI Cuts Deviation Investigations by 50%

Brent Wilhelm on Why Drug Shortages Persist Despite Available Inventory

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

The Implications of the FDA’s New Finalized Guidance Documents

Trending on Pharmaceutical Technology

FDA Activity Round Up – July 2026

Can Governance-by-Design Make AI Compliant in Pharma? (Part II)

From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026

Midyear 2026 Check-In: Agentic AI Cuts Deviation Investigations by 50%

Midyear 2026 Check-In: AI, Supply Chains, and the NDC-12 Story Nobody's Watching